Clinical Trials Logo

Filter by:
NCT ID: NCT05583227 Recruiting - Clinical trials for Eosinophilic Esophagitis

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

CROSSING
Start date: November 10, 2022
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo-controlled multicenter, phase 3 study to evaluate the efficacy and safety of tezepelumab administered subcutaneously (SC) using an accessorized pre-filled syringe (APFS) versus placebo in adult and adolescent patients with eosinophilic esophagitis (EoE).

NCT ID: NCT05583201 Recruiting - Pancreatic Cancer Clinical Trials

NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Start date: October 13, 2022
Phase: Early Phase 1
Study type: Interventional

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.

NCT ID: NCT05583175 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies

Start date: November 1, 2022
Phase: Phase 2
Study type: Interventional

This study is a single center, single arm, prospective, phase II clinical study to evaluate the efficacy and safety of Venatoclax combined with reduced intensity conditioning regimen allo-HSCT in the treatment of high-risk myeloid malignancies in the elderly patients.

NCT ID: NCT05583123 Recruiting - Partial-edentulism Clinical Trials

One-piece and Two-piece Zirconia Abutments in Single Implant Crowns in Esthetic Region

Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trail is to evaluate the clinical, radiological and immunological outcomes of the one-piece zirconia abutments (OPZAs) and two-piece zirconia abutments (TPZAs) with friction-fitted titanium bases in single implant crowns in aesthetic region. The main question it aims to answer is: whether the mechanical properties of one-piece zirconia abutments are the same as those of two-piece zirconia abutments. Participants who have two missing teeth in aesthetic region will receive the OPZAs for one restoration and the TPZAs for the other. Researchers will compare OPZAs group (OG) and TPZAs group (TG) to see the clinical, radiological and immunological outcomes of the two.

NCT ID: NCT05583058 Not yet recruiting - Gender Dysphoria Clinical Trials

Sex Hormone Overdose and Misuse in Chinese Transgender and Gender Non-conforming Population

HODMChina
Start date: December 15, 2022
Phase:
Study type: Observational [Patient Registry]

The investigators propose to investigate the definition of hormone overdose and misuse (HODM) in Chinese transgender and gender nonconforming population (TGNCs), address the incidence of HODM in Chinese TGNC population, related factors and risks, identify the probable causes of HODM, and follow up HODM individuals to explore long-term effects. The research questions are: Q1 What is the definition and the criteria of HODM in Chinese TGNC population? Q2 What is the prevalence of HODM in Chinese TGNC population? Q3 What factors and risks are relevant to HODM? Q4 What are the causes? Q5 What are the long-term effects of HODM in Chinese TGNC population, compared to those who enroll in regular GAHT regimens? The investigators decide to employ a mixed-methods design to construct a full research framework on HODM. A prospective cohort study is a component of the study. The study can be divided into four stages to address research questions. Stage I will establish a precise definition and eligibility criteria of HODM through expert panel meeting and stakeholder engagement. Subsequently, a cross-sectional study will be conducted to evaluate the rate, subtypes, and related factors of HODM in Chinese TGNCs. In Stage III, semi-structured interviews and focus groups for TGNCs who are identified as HODM will be employed to investigate the causes, motivations and personal impact factors. This stage will be divided into two phases, Stage III-a before the cross-sectional study to provide a brief picture of HODM behaviors, and Stage III-b after the cross-sectional study to draw an overall pattern. Lastly, all participants of Stage II or III who would like to participate in our follow-up will be included in prospective cohorts to assess long-term effects. Among the stages, the cohort study is the subject of the registration. The investigators propose two cohorts in the study. Participants who are identified as HODM will be assigned to cohort 1 [HODM cohort], and those who are identified as regular GAHT use will be assigned to cohort 2 [non-HODM cohort]. Participants will be asked to report their gender-related and hormone use-related conditions, and mental health-related conditions at specific timepoints. The investigators will compare the HODM cohort to the non-HODM cohort to see if the overall incidence of adverse effects, gender-related, hormone-related, and mental health-related conditions differ in the cohorts.

NCT ID: NCT05582629 Completed - Clinical trials for Mild to Moderate COVID-19

JT001 (VV116) for the Treatment of COVID-19

Start date: October 21, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) in participants with mild to moderate COVID-19.

NCT ID: NCT05582499 Recruiting - Breast Cancer Clinical Trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

FASCINATE-N
Start date: November 1, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.

NCT ID: NCT05582395 Active, not recruiting - Clinical trials for Cardiomyopathy, Hypertrophic

A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy

ODYSSEY-HCM
Start date: December 14, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM).

NCT ID: NCT05582291 Completed - Clinical trials for Postoperative Complications

Effect of Daytime Variation on PPCs in Lung Resection Surgery.

Start date: January 12, 2022
Phase:
Study type: Observational

The aim of this retrospective study was to evaluate the association between daytime variation in surgery start time and the occurrence of postoperative pulmonary complications (PPCs) and postoperative adverse events (AEs) in patients who underwent lung resection under general anaesthesia.

NCT ID: NCT05582278 Recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Drug-eluting Bead-Transarterial chemoembolization (D-TACE) is the most widely used palliative treatment for hepatocellular carcinoma (HCC) patients. While a number of studies demonstrate poor effect of D-TACE for patients in Advanced Unresectable HCC. The investigators previous study also revealed similar results in Advanced Unresectable HCC patients treated with D-TACE. Recently, the investigators previous study demonstrated that, compared with D-TACE, hepatic arterial infusion chemotherapy (HAIC) may improve tumor response in Advanced Unresectable HCC. Thus, the investigators carried out this prospective nonrandomized control to demonstrate the superiority of HAIC-based combination therapy over D-TACE-based combination therapy.